Astrazeneca Secures FDA Approval for New Breast Cancer Treatment
AstraZeneca secured FDA approval for its breast cancer drug Etcamah and reported positive Phase 3 trial data for lung cancer and COPD.
Stocks · News reference
AstraZeneca Announces Tozorakimab Demonstrates Reduction In Participants With Chronic Obstructive Pulmonary Disease In Phase III OBERON, TITANIA Studies
https://www.astrazeneca.com/media-centre/press-releases/2026/tozorakimab-demonstrated-statistically-significant-highly-clinically-meaningful-reduction-copd-exacerbations-oberon-titania-phase-iii-trials.html
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?
Merck's stock is trading near its 52-week high, driven by positive phase III data for its Keytruda-Moderna cancer therapy combo and strong fundamentals. Keytruda is expected to reach $35 billion in peak sales by 2028, with the company launching 20 new drugs by 2030. However, Merck faces significant headwinds including Keytruda's 2028 patent expiration, declining Gardasil vaccine sales, and generic erosion of diabetes and other drugs.
AstraZeneca Says Phase 3 DeLLphi-305 Interim Analysis Showed IMFINZI Plus Amgen's Tarlatamab Met Primary Endpoint With Statistically Significant Overall Survival Improvement vs. IMFINZI Alone In Extensive-Stage Small Cell Lung Cancer